方星 張信輝 劉水青 鄭燕 楊興林 付琳 柳興鳳
[關(guān)鍵詞] 人類免疫缺陷病毒;抗逆轉(zhuǎn)錄病毒治療;HIV-1 DNA;HIV-1 RNA;CD4+T淋巴細(xì)胞
[中圖分類號(hào)] R512.9? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701(2021)22-0152-04
Application of peripheral blood HIV-1 DNA in the evaluation of AIDS efficacy
FANG Xing1? ?ZHANG Xinhui1? ?LIU Shuiqing2? ?ZHENG Yan2? ?YANG Xinglin2? ?FU Lin1? ?LIU Xingfeng3
1.Guizhou Provincial Center for Disease Control and Prevention/Experimental Center, Guiyang? ?550000, China; 2. Guiyang Public Health Rescue Center, Guiyang? ?550000, China; 3.Zunyi Medical University/Key Laboratory of Brain Science Characteristics of of Guizhou Colleges and Universities, Zunyi? ?563000, China
[Abstract] Objective To study the relationship between HIV-1 DNA and HIV-1 RNA and CD4+T lymphocytes of HIV-infected persons, and to explore the application of peripheral blood HIV-1 DNA in the efficacy evaluation of AIDS. Methods A total of 80 HIV-infected patients in the Guiyang Public Health Rescue Center from June to September 2018 were selected. Face-to-face questionnaire surveys were used to collect patient data, and K2EDTA anticoagulant blood was collected from patients. The CD4+ T lymphocytes, HIV-1 The RNA and HIV-1 DNA were tested, and the results were obtained. The virus pool level of HIV-infected persons, the correlation between HIV-1 DNA and HIV clinical stage, CD4+T lymphocyte count and HIV-1 RNA were analyzed through SPSS. Results The higher the number of CD4+T lymphocytes in HIV-infected persons, the lower the HIV-1 RNA content and the lower the HIV-1 DNA level in their whole blood. The differences were statistically significant(P<0.05). Conclusion HIV-1 DNA can reflect the level of virus pool during antiretroviral therapy(HAART), suggest disease progression, and evaluate the effect of treatment. It can provide a more accurate monitoring method for AIDS treatment in Guizhou Province.
[Key words] Human immunodeficiency virus; Antiretroviral therapy; HIV-1 DNA; HIV-1 RNA; CD4+ T lymphocytes
高效聯(lián)合抗逆轉(zhuǎn)錄病毒治療(Highly active anti-retroviral therapy,HAART)通過有效抑制HIV復(fù)制,降低人體內(nèi)病毒載量,重建患者免疫功能,顯著降低了HIV相關(guān)疾病的發(fā)生率和病死率[1-2]。目前,艾滋病抗病毒治療已證實(shí)是最有效的治療手段[3],一旦停藥,多數(shù)患者2周左右便會(huì)出現(xiàn)外周血病毒反彈,使得HIV患者需要終身堅(jiān)持HAART治療,且存在著藥物毒副作用、耐藥、依從性差及沉重的經(jīng)濟(jì)負(fù)擔(dān)等問題。有研究顯示,在 HIV 感染早期 HIV-1 DNA就已經(jīng)整合到感染細(xì)胞中并持續(xù)存在,形成病毒儲(chǔ)存庫(Reservoir),而被整合的感染細(xì)胞處于靜息狀態(tài),不表達(dá)病毒蛋白,不被體內(nèi)免疫細(xì)胞識(shí)別,亦不受抗病毒治療的影響,可在感染者體內(nèi)長期存在,因此雖然通過HAART能夠有效降低血漿艾滋病病毒載量,但因 HIV-1 DNA 的持續(xù)存在不能徹底清除體內(nèi)的病毒,從而造成HIV感染難以治愈[4-7]。目前,HIV病毒儲(chǔ)存庫造成艾滋病病毒的反彈已被廣泛認(rèn)同是HAART無法徹底清除HIV和治愈艾滋病的主要原因[8]??刂艸IV病毒儲(chǔ)存庫可能成為艾滋病功能性治愈的新策略[9-11]。根據(jù)已成熟的方法[12],本研究旨在通過研究HIV感染者HIV-1 DNA與HIV-1 RNA及CD4+T淋巴細(xì)胞間的關(guān)系,探討外周血HIV-1 DNA在艾滋病療效評(píng)估中的應(yīng)用。為實(shí)現(xiàn)貴州省的“三個(gè)90%”和艾滋病的治療提供更精準(zhǔn)的監(jiān)測手段,現(xiàn)報(bào)道如下。